Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Rises By 117.6%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 6,872 shares, a growth of 117.6% from the May 31st total of 3,158 shares. Based on an average daily volume of 38,353 shares, the days-to-cover ratio is currently 0.2 days.

SAB Biotherapeutics Stock Down 0.7%

SAB Biotherapeutics stock opened at $0.01 on Tuesday. The firm’s fifty day moving average price is $0.02 and its two-hundred day moving average price is $0.03. SAB Biotherapeutics has a 1-year low of $0.01 and a 1-year high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.